Skip to Content

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX)

Merger

  • Date:
  • 10/2/2019
  • Company Name:
  • Progenics Pharmaceuticals, Inc.
  • Stock Symbol:
  • PGNX
  • Company Name - Buyer:
  • Lantheus Holdings, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 10/2/2019

Case Finder

Locate any case using the tools below.

NEW YORK, October 2, 2019 – Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on behalf of Progenics shareholders concerning the proposed merger with Lantheus Holdings, Inc.

Pursuant to the proposed transaction announced on October 2, 2019, Progenics shareholders will receive 0.2502 shares of Lantheus common stock for each share of Progenics common stock owned.  The investigation focuses on whether Progenics and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

If you own Progenics shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Alexandra Raymond by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Progenics Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: